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aBackground. Late complications of the Fontan opera-
ion represent a significant management challenge. Fail-
ng Fontan patients have two modes of presentation:
mpaired ventricular function (IVF) and those with pre-
erved ventricular function (PVF) but with failing Fontan
hysiology (protein-losing enteropathy [PLE] and plastic
ronchitis [PB]). This study evaluated whether failing
ontan patients referred for heart transplantation had a
ifferent outcome based on the mode of presentation.
Methods. The medical records of all Fontan patients
valuated for heart transplantation at a single institution
rom 1994 to 2008 were retrospectively reviewed. Demo-
raphic, hemodynamic, and laboratory data were col-
ected. Patients were stratified into an IVF or PVF group
y echocardiographic criteria. Descriptive statistics and
aplan-Meier analysis were used for hypothesis testing.
Results. Thirty-four Fontan patients were evaluated for
eart transplantation. According to echo description of
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2009 by The Society of Thoracic Surgeons
ublished by Elsevier Incystolic function, 18 were categorized as IVF and 16 as
VF. The IVF group had a significantly lower cardiac
ndex and venous oxygen saturation, and significantly
igher systemic vascular resistance vs the PVF group
p < 0.05). PLE or PB was present in 13 PVF patients and
one in the IVF group. Twenty patients underwent
ransplantation, with similar rates amongst the IVF and
VF groups. Within 1 year from evaluation, 2 IVG
atients and 7 PVF patients had died (p  0.052).
Conclusions. Failing Fontan patients with PVF have
ecreased overall survival independent of whether they
nderwent transplantation. This trend indicates a need to
mprove the management and timing for transplantation
mongst this population.
(Ann Thorac Surg 2009;88:558–64)
© 2009 by The Society of Thoracic Surgeonsn 1968 Fontan and Baudet introduced total right heart
bypass achieved with atriopulmonary connection in a
atient with tricuspid atresia—the first Fontan [1, 2].
ince that time, palliation of functional single ventricles
as undergone many revisions to improve survival and
ecrease long-term morbidity [3, 4].
Although survival has improved markedly since the first
alliative operations, these patients are still at increased
isk of late morbidity and death [5]. Late complications of
ontan palliation include progressive ventricular dysfunc-
ion, atrioventricular (AV) valve regurgitation, progressive
yanosis, thromboembolism, protein-losing enteropathy
PLE), plastic bronchitis, atrial tachyarrhythmias, and Fon-
an pathway obstruction [6–9]. If medical, surgical, and
atheter-based interventions are unable to improve symp-
ccepted for publication March 26, 2009.
resented at the Forty-fifth Annual Meeting of The Society of Thoracic
urgeons, San Francisco, CA, Jan 26–28, 2009.
ddress correspondence to Dr del Nido, Department of Cardiac Surgery,oms, cardiac transplantation may provide the only thera-
eutic treatment for many of these patients [5, 9–11].
The factors contributing to heart failure or failing
ontan physiology in patients with a Fontan repair re-
ain poorly defined. Identifying which factors may con-
ribute to death or increased risk of failure requiring
edical or surgical intervention is difficult because Fon-
an patients are a heterogeneous group that differ in
nderlying anatomic malformation, type of Fontan oper-
tion, age at Fontan operation, and eras in which opera-
ions were performed. Understanding these factors will
id in the management decisions for these complex
atients.
Amongst the failing Fontan patients, systolic ventricu-
ar dysfunction is a major indication for heart transplan-
ation [12]. Other patients, however, have relatively pre-
erved systolic ventricular function but present with
omplications of failed Fontan physiology, such refrac-
ory ascites, pleural effusions, PLE, and plastic bronchitis
8, 12, 13]. Because these conditions persist in the setting
f relatively normal cardiac output, heart transplantation
ay not have an immediate effect on the course of the
0003-4975/09/$36.00
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Cisease. Furthermore, the long-term consequences of
alnutrition, immunosuppression, and pulmonary com-
lications associated with PLE and plastic bronchitis may
ncrease the risks of heart transplantation in these pa-
ients. Because of these findings we hypothesized that
atients with failed Fontan physiology and preserved
entricular function are at increased risk of dying, both
efore and after cardiac transplantation.
atients and Methods
he study was conducted in accordance with institutional
uman Subjects Committee guidelines and was ap-
roved by the Institutional Review Board. The need for
ndividual consent was waived. The authors had full
ccess to the data and take full responsibility for their
ntegrity. All authors have read and agree to the manu-
cript as written.
Patients were identified by search of the Children’s
ospital cardiovascular program database for patients
ho had undergone a Fontan operation at any institution
ut were evaluated for heart transplantation at Chil-
ren’s Hospital Boston between January 1, 1994, and
anuary 1, 2008. The criterion for referring the patient for
eart transplant evaluation was physician-dependant.
ll patients had been discharged from the hospital, were
ore than 60 days from the time of last Fontan operation,
nd had at least 6 months of follow-up from the time of
able 1. Comparison of Impaired Ventricular Function vs Pre
haracteristic Impaired (n 
ge at evaluation, yb 12.8  5.9 (2.3–
ime since Fontan, yb 8.8  5.2 (0.2–
ale sex, No. (%) 12 (66.7
ongenital heart defect, No. (%)
TA 4 (22.2
DORV 5 (27.8
HLHS 6 (33.4
DILV —
Other 3 (16.7
ontan procedure, No. (%)
Lateral tunnel 15 (83.3
Atriopulmonary 2 (11.1
Extracardiac conduit 1 (5.6)
ystemic ventricle, No. (%)
Right, n (%) 12 (66.7
AV valve regurgitation
Moderate to Severe 10 (55.6
acemaker, No. (%) 5 (27.8
lastic bronchitis, No. (%) 0
LE, No. (%) 0
p  0.05 considered significant. b These data are presented as mean
V  atrioventricular; DILV  double-inlet left ventricle; DORV
LE  protein-losing enteropathy; TA  tricuspid atresia.valuation. The study excluded patients who had a pre-
s
pious Fontan takedown to a superior caval-pulmonary
nastomosis (bidirectional Glenn).
A detailed retrospective review was conducted of all
edical records. Demographic data, including inpatient,
linic, and operative notes, were collected. Laboratory,
unctional, and hemodynamic data, including cardiac
d Ventricular Function With Heart Failure
entricular Function
p ValueaPreserved (n  16)
10.9  6.0 (4.6–26.1) 0.54
6.1  6.2 (0.2–24.8) 0.17
9 (56.3) 0.533
0.251
2 (12.5) ...
7 (43.75) ...
5 (31.3) ...
2 (12.5) ...
... ...
0.596
11 (68.8) ...
3 (18.8) ...
2 (12.5) ...
12 (75.0) 0.715
...
1 (6.3) 0.006a
6 (37.5) 0.545
5 (31.3) 0.016a
9 (56.3) 0.001a
(range).
ble-outlet right ventricle; HLHS  hypoplastic left heart syndrome;
able 2. Comparison of Hemodynamic and Laboratory Data
haracteristic
Ventricular Function,
Mean  SD
p Valuea
Impaired
(n  18)
Preserved
(n  16)
ardiac index, L/min/m2 2.25  0.38 3.12  0.86 0.001a
aO2, % 86.5  6.7 85.6  6.4 0.767
vO2,% 56.5  8.5 63.6  8.0 0.020
a
ontan pathway, mm Hg 17.4 5.4 17.4  6.4 0.831
CWP, mm Hg 13.8  5.1 14.3  6.5 0.814
VR, Wood U 27.1  12.2 18.7  8.5 0.032a
VR, Wood U 2.3  0.9 2.9  1.0 0.112
emoglobin, mg/dL 16.0  1.6 14.4  2 0.027a
reatinine, mg/dL 0.78  0.24 0.74  0.70 0.853
lbumin, mg/dL 3.6  0.5 2.4  0.8 0.002a
p  0.05 considered significant.
vO2  mixed venous saturation; PCWP  pulmonary capillary
edge pressure; SaO2  saturation of arterial oxygen; SD serve
V
18)
19.9)
16.9)
)
)
)
)
)
)
)
)
)
)
 SDtandard deviation; SVR  systemic vascular resistance; PVR 
ulmonary vascular resistance.
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Catheterization and echocardiographic data, were ana-
yzed. Patient survival and transplant status were also
ecorded. Because many patients underwent subsequent
unctional and hemodynamic testing after transplanta-
ion evaluation, only data available at the time of trans-
lant evaluation were collected for analysis. The type of
ontan was classified as right atrium to pulmonary artery
nastomosis, a lateral tunnel, or extracardiac conduit.
AV valve anatomy and systemic ventricular morphol-
gy were categorized according to previously defined
omenclature on the basis of preoperative studies and
urgical findings. Cardiac function was evaluated by
-dimensional (2D) echocardiography and cardiac cath-
terization. Ventricular dysfunction was defined qualita-
ively as none, mild, moderate, or severe by a clinician
ot involved in the care of the patient. AV valve regur-
itation was graded by echocardiography as mild, mod-
rate, or severe based on the width of the Doppler color
ow jet and the extent of the regurgitation into the
trium.
tudy Cohorts
he patient cohort was divided into two groups based on
D echocardiographic findings of ventricular systolic
unction. Patients who were diagnosed with moderate to
evere ventricular dysfunction were assigned to the im-
aired ventricular function (IVF) group. Patients with
ild or no ventricular dysfunction were assigned to the
reserved ventricular function (PVF) group. The diagno-
is of PLE required the following criteria: hypoalbumin-
mia ( 3.0 mg/dL) for 3 months or longer in the absence
f liver or renal disease and accompanying ascites, pleu-
al effusions, edema, diarrhea, or abdominal pain for 3
onths or longer [7, 14]. Plastic bronchitis was diagnosed
y recurrent formation of branching bronchial casts of
he tracheobronchial tree [8, 15].
tatistical Analysis
he unpaired t test was used to compare the continuous
ariables of age at evaluation, time since Fontan opera-
ion, and pretransplantation laboratory values and hemo-
ynamics, including cardiac index, systemic oxygen sat-
ration, Fontan pathway pressures, pulmonary vascular
esistance, and systemic vascular resistance. Continuous
ariables were expressed as mean  standard deviation,
nless otherwise stated. Categoric variables, including
ig 1. Flow chart shows how patients were listed
or transplantation.ender, anatomic classification, left vs right ventricle aominance, ventricular dysfunction, AV valve regurgita-
ion, PLE, plastic bronchitis, arrhythmias, and use of
acemaker, were summarized as proportion  standard
eviation and compared using the Pearson 2 test and,
here appropriate, the Fisher exact test. The Bonferroni
orrection was used to account for multiple comparisons.
To estimate proportional survival after evaluation for
ransplantation, a Kaplan-Meier analysis was performed
n which patients with PVF were compared with individ-
als with IVF. Survival was further compared between
atients who had and had not undergone transplantation
o estimate the overall outcome in both groups, including
eath after transplantation. Statistical significance was
nferred at a 2-sided value of p  0.05. The statistical
nalyses were computed with STATA 10.1 software
StataCorp, College Station, TX).
esults
roup Characteristics
he 34 patients who met the study criteria were divided
nto two groups according to ventricular function by
chocardiography: 16 with PVF complicated by failed
ontan physiology, and 18 with IVF. The baseline char-
cteristics of the two groups are summarized in Table 1.
here were no differences in mean age at heart trans-
lantation evaluation or time since Fontan operation
Table 1). The types of Fontan operations were similar in
oth groups. Systemic right ventricle was present in
6.7% of IVF and 75.0% of PVF. Arrhythmia complica-
ions requiring pacemaker implantation were similar in
oth groups. The PVF group was complicated by PLE
nly in 8 patients, plastic bronchitis only in 5 patients, 1
able 3. Comparison of Mortality
haracteristic
Ventricular Function,
No. (%)
p Valuea
Impaired
(n  18)
Preserved
(n  16)
ransplanted 11 (61.1) 9 (56.3) 0.774
eaths, n (%) 2 (11.1) 7 (43.8) 0.052a
Transplanted 0/11 3/9 (33.3) 0.074a
Non-transplanted 2/7 (28.6) 4/8 (50) 0.473p  0.05 considered significant.
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Catient with both PLE and plastic bronchitis, and 3 were
omplicated by ascites, pulmonary edema, or pleural
ffusions, or both, but did not meet our criteria for the
iagnosis of PLE or plastic bronchitis. No PLE or plastic
ronchitis was present in the IVF group with failing
ontans.
Table 2 reports the comparison of hemodynamic and
aboratory data. The IVF group had significantly lower
ardiac index and mixed venous saturation, and higher
ystemic vascular resistance. There was no difference in
ontan baffle pressures, caval pressures, or pulmonary
apillary wedge pressures. Moderate to severe AV valve
egurgitation was present in 55.6% of IVF patients com-
ared with 6.3% (p  0.006) in the PVF group. Once a
atient was referred for transplant, no AV repair was
ttempted. Laboratory data were only significant for an
ncreased hemoglobin level in the IVF group and signif-
cantly decreased albumin in the PVF group (Table 2).
urvival
f the 34 patients identified in this study, 24 were listed
or transplantation (Fig 1). The rates of listing and trans-
lantation were similar in both groups (Table 3). The wait
ist time was 178 days for IVF and 192 for PVF, which was
ot significant (p  0.87). Of the 4 patients not listed for
ransplantation in the IVF group, 3 were considered “too
ell” for listing based institutional criteria, and 1 patient
as ineligible because of multiple medical risk factors,
hich included a combination of multiple risk factors
ig 2. Actuarial survival from time of evaluation for heart trans-
lantation in patients with impaired ventricular function (IVF, solid
ine) and preserved ventricular function (PVF, dotted line). Patients
ere censored at the last follow-up. Mean follow-up was 55.2  50
onths.
able 4. Cause of Death
ause
Ventricular Function, No. (%)
Impaired (n  2) Preserved (n  7)
ardiac failure 1 (50) 2 (29)
ultiorgan failure 1 (50) 2 (29)
cute graft failure ... 2 (29)d
nknown ... 1 (14)uch as renal dysfunction, high pulmonary vascular re-
istance, lung disease, or liver cirrhosis. Of the 14 pa-
ients listed for transplantation in the IVF group, 2 died
efore transplantation, 11 received a transplant, and 1
atient was currently listed and awaiting transplantation.
In the PVF group, 10 of 16 patients were listed for
ransplant, 9 underwent transplantation, and 3 died
33%) early after the transplant. The tenth patient was
elisted because his conditioned improved. Seven PVF
atients were not listed for transplantation: 4 were con-
idered ineligible by standard institutional criteria as
isted above (ie, “too sick”), 2 were eligible but consid-
red “too well,” and 1 patient refused. The 4 patients who
ere “too high risk” for transplantation died.
Overall, there were 7 deaths (43.8%) in the PVF group
ompared with 2 deaths (12.5%) in the IVF group (p 
.052) during a mean follow-up of 55.2  50 months
Table 3). Overall survival determined by Kaplan-Meier
nalysis (Fig 2) demonstrated patients with PVF with
ailing Fontan physiology had significantly worse mid-
erm survival than patients with IVF. All deaths occurred
ithin 1 year after the transplant evaluation, demonstrat-
ng a 1-year actuarial survival of 88.9% in the IVF group
nd 56.2% in the PVF group (p  0.042).
There were no significant differences in the causes of
eath between the two groups listed in Table 4. In the
VF group with failed Fontan physiology, 3 of the 7
eaths occurred in transplant recipients. Two patients
ied of acute graft failure without evidence of cellular
ejection, and 1 died of multiorgan failure. Two of the
atients were diagnosed with plastic bronchitis and 1
ith PLE. The remaining deaths in the PVF group oc-
urred in those not listed for transplantation, with a
edian time from evaluation to death of 142.5 days
range, 6 to 252 days). Cardiac failure was reported as the
ause of death in 2 patients, multiorgan failure in 1, and
he cause of death was unknown in 1 patient. Cardiac
ailure and multiorgan failure also accounted for the 2
ig 3. Actuarial survival is shown for patients who underwent
ransplantation (solid line) and those who did not (dotted line). Pa-
ients were censored at the last follow-up. Mean follow-up was 55.2 
0 months.eaths in the IVF group.
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Cffects of Transplantation
o examine the effects of transplantation on survival in
ll single-ventricle palliation patients referred for trans-
lantation, we analyzed the overall survival of those who
eceived a transplant vs those who did not. Of the 34
atients evaluated, 24 were listed for transplantation and
0 received a transplant. Death occurred in 3 of the 20
atients (15%) who received a transplant and in 6 of the
4 patients (42.9%) who did not receive a transplant (p 
.064; Fig 3). Survival analysis showed a strong trend
owards improved survival in those patients who re-
eived a transplant.
omment
anagement of late failure of Fontan palliation is a
ignificant challenge, with transplantation often being
he only available option. In addition, there are currently
o standard mechanical ventricular assist strategies for
his complex group of patients. Of the failed Fontan
atients referred to our center for transplant evaluation,
e found that categorizing them on the basis of ventric-
lar systolic function, as determined by echocardiogra-
hy, correlated strongly with the presence or absence of
econdary sequelae of failed Fontan physiology such as
LE, plastic bronchitis, and refractory ascites and edema.
urthermore, survival was significantly decreased in the
atients who presented with PVF but with signs and
ymptoms of failed Fontan physiology such as ascites,
dema, and pleural effusions. The possible cause for this
oncerning finding remains speculative, because a wide
ange of variables including type of systemic ventricle,
acemaker dependency, atrial tachyarrhythmias, age at
ontan, and time since follow-up on univariate analysis
id not show statistically significant risk.
Because PLE and plastic bronchitis were only found in
he PVF group, it is tempting to impugn these two
onditions as likely contributors. PLE is a devastating
omplication of Fontan physiology, with 50% mortality
ithin 5 years after diagnosis [13, 16]. Multiple treatment
odalities exist that likely reflect the paucity of definitive
anagement principles based on a clear understanding
f its cause [17]. Bernstein and colleagues [9] reported that
LE symptoms improved in 100% of patients who survived
he initial period after transplantation, making a compelling
rgument for use of transplantation as a final treatment
odality for refractory PLE [9]. Others have also docu-
ented an improvement in PLE after transplantation [18].
owever, a recent review of long-term survival in patients
ith Fontan operations found PLE was an increased risk
actor for death [7]. We found 33% of patients with PLE
ied: 2 before transplantation and 1 after.
In our study, 5 patients evaluated for heart transplan-
ation were diagnosed with plastic bronchitis, with 3
eaths overall—2 after transplantation—during the fol-
ow-up period. Plastic bronchitis is becoming an increas-
ngly recognized complication of congenital heart disease
nd particularly Fontan patients. Little is known about
he cause of this difficult condition, and multiple thera- gies have been advanced without a clear consensus on
he best management [15, 19, 20]. Furthermore, there are
ew data examining its role in Fontan failure or contribu-
ion to death after transplantation. We are limited by the
mall sample size; however, the results are concerning
nd point to the need for further study into the natural
istory of plastic bronchitis, including possible resolution
fter heart transplantation.
Three patients with PVF lacked the diagnosis of plastic
ronchitis or PLE but had significant complications of
leural effusions, edema, and refractory ascites. These
atients did not meet the stringent criteria for diagnosis
f PLE in this study but could represent a spectrum of
isease with PLE as the extreme manifestation [13]. The
alidity of grouping these patients is yet to be proven,
lthough PLE and plastic bronchitis may share a similar
ause [12, 21, 22].
IVF is a well-recognized indication for transplantation
12, 18]. In our study, 47% of patients were classified as
aving IVF by echocardiography and confirmed by cath-
terization, consistent with other reported rates of ven-
ricular dysfunction [12]. Prior studies have suggested
hat progressive ventricular dysfunction is more common
ith the right ventricle [23, 24]. The morphologic right
entricle was the systemic ventricle in approximate two
hirds of all patients in our study, with equal distribution
n both the PVF and IVF groups. By log-rank test, a
ystemic right ventricle was not significantly associated
ith decreased survival.
All deaths within our study occurred within 1 year
rom the time of referral for transplantation, indicating
hat these patients are very sick at the time of evaluation.
urvivors from the early period had equivalent midterm
urvival, indicating the increased risk of dying for those
ith PVF and failed Fontan physiology is in the early
ime period. Earlier referral of these patients may limit
he negative consequences of the noncardiac complica-
ions of failed Fontan physiology such as PLE and plastic
ronchitis, which could contribute to the increased mor-
ality rate.
Our study has several limitations. First, the small
ample size in each subgroup may limit detection of
tatistically significant differences. In addition, the study
s limited by its retrospective nature. In particular at our
arge institution, the criteria for referral for cardiac trans-
lantation evaluation are not standardized. This may
ontribute to the differences in outcome between the two
roups, because one group may have been referred later.
In addition, certain eligible patients may have been
xcluded because of practitioner bias. Possible consider-
tions include those who are thought to be too sick or too
igh risk for transplantation, or those whose families are
ot interested in transplantation as a therapeutic option
nd therefore referral was not made. More standardized
riteria for evaluation are needed in late Fontan patients
efore we can definitively answer those who benefit most
r are at greatest risk during heart transplantation.
Finally, the study is limited by the use of echocardio-
raphic estimates of systolic function in single-ventricle
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Catients and the difficulty in estimating the contribution
f diastolic function to the pathology.
As increasing numbers of patients are palliated with
ontan operations, the number of children, adolescents,
nd young adults requiring late rescue therapy with
eart transplantation will increase [11]. The sparse avail-
bility of hearts for transplantation and the associated
orbidities with immunosuppression make it imperative
hat it is used appropriately. Therefore, much benefit
ould be derived from identifying those patients with
ailing Fontan physiology who might benefit from other
odes of therapy and optimizing the timing of transplan-
ation to exact the greatest benefit from such a scarce
esource. Further study of diastolic dysfunction after the
ontan procedure may further clarify high-risk patients.
n addition, developing ventricular support devices that
ay bridge patients more successfully are needed. It may
e possible to better prepare the Fontan pulmonary
irculation over months with pulsatile flow to better
elect patients for improved transplant outcomes.
In conclusion, patients referred for transplant evaluation
ith failing Fontan circulation have two different modes of
resentation and can be categorized on the basis of their
entricular systolic function. This method of categorization
dentifies a group at higher risk that also presents with
equelae of failed Fontan physiology including PLE, plastic
ronchitis, refractory ascites, and edema. This high-risk
roup has a greater than threefold risk of death within 1
ear compared with the group that presents with poor
entricular function. Earlier referral for transplantation or
lternative medical or surgical interventions should be
onsidered for the high-risk group.
r Griffiths was supported by the Harvard-Longwood Research
raining in Vascular Surgery: T32 HL 007734 to FW Logerfo.
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as a terrific presentation. I wonder if you could comment onith the preserved ventricular function who were for the most
art patients with protein-losing enteropathy [PLE] and plas-
ic bronchitis, did they die in that first year of failure to make
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Csatisfactory recovery from transplantation because of the
oor condition of their protoplasm and other organ systems,
r did they die of persistence of PLE and plastic bronchitis or
f other factors?
R GRIFFITHS: The cause of death did not differ between the
wo groups. There were 3 posttransplant deaths total, all in the
reserved function group. Two of those patients had plastic
ronchitis and one had PLE. The cause of death was categorized
s cardiac failure in 2 patients and multisystem failure in 1
atient. We did not follow the patients after transplantation for
esolution of symptoms.
R CARL L. BACKER (Chicago, IL): That was a very nice
nalysis. I have two questions. I think our experience with
ransplanting the patient with a failed Fontan is that one of the
ardest things to do is to say ”No” to the potential recipient.
ypically, this is a patient that you have been caring for in your
rogram for many years. The mortality that we have had in our
eries has been the very sick patient that finally gets referred for
ransplantation and then you just can’t say ”No.” The question I
ave relates to that. It looks to me like you said ”No” quite a bit,
ecause 40% of the patients that came for evaluation you
eclined to list. What happened to those patients?
R GRIFFITHS: In the impaired ventricular function group, 14
atients were listed, and 4 were not listed—3 were considered
oo well and 1 was considered too sick. And all of those patients
urvived. Of the 14 listed, 11 were transplanted, all of those
urvived. In the nontransplanted group, 2 were considered too
ick and subsequently died, and 1 is awaiting transplantation. In
he preserved function group, 6 were not listed—4 were consid-
red too sick and subsequently died.
R BACKER: How long did it take them to die?
R GRIFFITHS: All deaths occurred within the first year. The
ean time to death was 102 days, with a range from 6 to 252 days.
R BACKER: The second thing that came out of our analysis
as that the combination of a failed Fontan and renal failure was
eally a bad combination and that predicted a mortality in our
eries of 66%. Did you have any patients that had—because
enal failure frequently goes along with a failed Fontan—did
ou have patients with renal failure and what happened in that
roup?
R GRIFFITHS: We didn’t have any with overt renal failure.
he mean creatinine was 0.7 mg/dL and did not differ between
he two groups. We didn’t look at creatinine clearance, which is
robably a better marker to get an indication of their renal
unction. Creatinine didn’t fall out as a risk factor for death in
he cohort.
R EMRE BELLI (Le Plessis-Robinson, France): I have a comment
nd a question. Our experience is totally different. Probably we
ransplant very early the PLE or bronchitis patients and too late in
ailing Fontan patients who are having big problems postopera-
ively, notably renal failure. My question, did you consider or try
urgical or percutaneous fenestration before listing for transplant
his group of patients with PLE or plastic bronchitis?
R GRIFFITHS: I am sorry. I don’t have that information as to
hat the algorithm was in managing these patients. That was
art of the difficulty is figuring out what to do with these patients sith PLE and plastic bronchitis. I think it is easier when a patient
as ventricular dysfunction and they are starting to fail. You
ave a better idea of when to refer them for a transplant. With
hese patients with PLE or plastic bronchitis, when are they sick
nough that they need transplantation? At what point do we
eed to be sending these to transplant before they get too sick?
he fact that all these died within the first year means that we
ere looking at a very sick population.
R FRANK PIGULA (Boston, MA): In terms of trying to get at
hat question, as you know, there have been very conflicting
esults about relieving or fenestrating a Fontan in those circum-
tances, although that has been tried in many of these patients.
ome have gone to the cath lab for fenestration and stenting,
hile others have gone to the operating room. The results have
een unpredictable.
And the way I think about these data that he has presented is
hat there is almost two different disease processes. In the first,
he failure is in the myocardium and in the heart, and in the
econd is a failure in the in the body. And I think we are very
ood at picking up systolic failure in the myocardium. I don’t
hink we are very good at understanding when you reach a
ipping point in the failure of the body to accept that physiology.
nd I think that is the striking thing, to me, about the data that
e has presented.
That one slide that you showed back earlier where there was
lmost a clear-cut demarcation between the 2 groups. In patients
ith failing systolic function, there was no plastic bronchitis or
LE, while in patients with preserved systolic function, and a
hird to a half of these patients had this.
R ANTHONY AZAKIE (San Francisco, CA): Does that refer to
ystolic and diastolic function?
R GRIFFITHS: This is systolic function. This is echo data.
R AZAKIE: So ”preserved function” can include diastolic
ysfunction, right?
R GRIFFITHS: Correct. But by echo and cardiac catheteriza-
ion these patients had good cardiac systolic function.
R JOHN LAMBERTI (San Diego, CA): The fact that everybody
s still here even though it is the last paper suggests that this
opic is very important and of great interest to all of us. Can you
o to the next slide? In Jack Rychik’s unified theory of PLE, the
ardiac index is low. In your cases, the cardiac index is preserved
n the PLE patients. This finding contradicts the idea that all PLE
atients have impaired cardiac output. Overall, it is a very
onfusing picture, at least in my mind.
Speaking anecdotally, we have had some patients with PLE
hat responded very well to creation of a fenestration in the cath
ab. When their sats go up, they have more PLE; and when they
et their fenestration dilated, they are a little bluer and they feel
etter. So fenestration is useful in some patients.
R BELLI: I will just add an experience. We had a 15-year-old
atient, who previously developed pulmonary AV [arterio-
enous] fistula, after kind of a Kawashima connection. We
unneled first the hepatic veins to the systemic venous chamber,
hen she developed PLE and we did a redo with direct connec-
ion using an extracardiac conduit. She was postoperatively
kay, but she restarted PLE and that stopped, surprisingly, with
edical treatment by Viagra (sildenafil). We fixed her PLE and
he is okay now.
